Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05378100 (ClinicalTrials.gov)	January 1, 2023	12/5/2022	Ketamine for Multiple Sclerosis Fatigue	Low-Dose Ketamine Infusion for the Treatment of Multiple Sclerosis Fatigue (INKLING-MS)	Multiple Sclerosis Fatigue	Drug: Ketamine;Drug: Midazolam	Johns Hopkins University	United States Department of Defense	Recruiting	18 Years	65 Years	All	110	Phase 2	United States
2	NCT03500289 (ClinicalTrials.gov)	August 10, 2018	4/4/2018	Ketamine for Treatment of MS Fatigue	Ketamine for Treatment of Multiple Sclerosis-related Fatigue	Multiple Sclerosis;Fatigue	Drug: Ketamine;Drug: Midazolam	Johns Hopkins University	National Multiple Sclerosis Society	Completed	18 Years	65 Years	All	18	Phase 1/Phase 2	United States
3	NCT01462318 (ClinicalTrials.gov)	November 2011	14/7/2011	An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis	A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics of BIIB019, Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis	Drug: Midazolam;Other: Caffeine;Drug: S-warfarin;Other: Vitamin K;Drug: Omeprazole;Drug: Dextromethorphan;Biological: BIIB019 (Daclizumab)	Biogen	NULL	Completed	18 Years	65 Years	All	133	Phase 3	United States;Czech Republic;Hungary;Poland;Russian Federation